progress have great to quarter It’s call. made eventful a fronts. second where and our Thank you, Good we welcome afternoon, Jackie. been an number quarter on of
based FDA Separately, with confirmatory post-marketing third thorough the from XXXX that on second pre-NDA which our discussion FDA, in TRCA-XXXE submission trial the Program the under the trial included and our of the recent First, NDA we results. positive we the Accelerated to significant are of VALOR-CKD. timing for our of made we’ve narrowing planned with our progress meeting enrollment a updating half discussed the Approval quarter the
by sufficient was our XXXX. intend the Tricida randomizing plan the the We for fully in our patient the for overall to trial. to enrollment in submission update While on VALOR-CKD the of deemed is enrolled, an yet not quarter trial year NDA estimates by FDA the provide this progress for third last of end the
we basis know, Program that translates our the of the serum surrogate pursuing under demonstrate increase endpoint Accelerated ongoing to you Approval initial clinical on As post-marketing approval to of are bicarbonate benefit. with an the commitment surrogate endpoint
XX-week The publications trials Fast now pillars XX-week The our Lancet’s the XXXE Phase Lancet. clinical based placebo-controlled have weeks. as of speaks commitment double-blind, X.X into on multi-center the as in believe important was in and arena The that accepted manuscript program back-to-back health The XXXE in including submission presented extension blinded data review, results publication are for of peer placebo-controlled, III data. been the to were to to quickly published manuscript the importance editing From public publication, publication, and get possible. this this full We Track
a without favor in that for to the product death/dialysis Figure of showing shows confirmed a XX% presented veverimer eGFR in than or time placebo, survived In the Kaplan-Meier after decline a data a It of endpoint to first on starting prespecified event part separation the more for the XX compared patients X survival of time analysis with of veverimer longer from is composite time. weeks. DDXX paper,
shows improvement. a X- physical the to weeks functions walk including difference ability activities, multiple in to Lancet in to flight improvement at the important minimum blocks clinically climb that improvement patients veverimer XX-point and improvement The XX. veverimer-treated XX multiple stairs, XX exceeding an week a X-point of self-reported was group the Figure X that mean had in starting of sustained continued The and of
to up chair the ability week in improvement XX. starting veverimer minimal XX, chair repeated their physical that set a XX, veverimer-treated a objectively and improved Figure X.X at stand difference experienced the function five as from the on improvement group by was clinically times, and week seconds. important shows X.X-second test stand at XX of weeks At continued exceeding seen measured XB the also
effect mechanism have I’ve presented increase included have only been treatment journals. results publication. of highlights this bicarbonate allowed most here clinical placebo-controlled, data publication. other these potential some the with These removal. can first metabolic beyond in of binding found findings and us the acid of of our surrogate on publications of in blinded, action the acidosis very in published Details multi-center the uses to now and the Lancet high-impact well-respected, recent share data novel three be of trials exciting the and serum that All
health. longer physical with endpoint showing the function to results treating and link improved metabolic are to we time clinical bone kidney believe, body composite and, of the and improving add overall acidosis DDXX basic muscle, acidosis The between pathophysiology of of the evidence metabolic consistent
generated European website. like attention XXX oral study multi-center, a of double-blind, Results group with data CKD with acidosis some trial Dundee bicarbonate. bicarb first your been available to mild of placebo-controlled this The by University sodium England. patients Clinical would metabolic have to we and the study in made Trials call recent Next, randomized, on the Register of is the associated from
patients in Dr. is to patients randomized study, oral of trials The matching placebo. online, Witham XXXX. protocol and study to X.X colleagues which for in was Miles XXX available X by XXX to sodium The published grams bicarbonate and the
speed is highest treatment. composed was the for the Performance measure after a The five composite times and X of group Short the trial three extremity X those points between score, The Physical maximum Battery a primary contributes test repeated being the XX. test, and endpoint SPPB physical with year Each score difference in gait components of balance from or function function to SPPB stand SPPB a score change the and of one of lower assessment. better chair patient’s indicating to score the the
At years, Baseline the XX centers in XX XX was per was study enrolled eGFR minute, SPPB milligrams and on XX were of both averaged eight groups. per the serum bicarbonate scores milliliters XX to was mean at mean baseline, UK. XX liter. the subjects average to The approximately population in the age the study the
the points Approximately half each reasons X.X – participants from were study. group early most treatment, the group difference The time increased after of with between point. withdrew two-year different treatments. group levels placebo indicating placebo small the too, also subject comparison X.XX, months of bicarbonate the X.X a and a bicarbonate discontinuation quality life, the prespecified in common serum by at adverse years from showed consent significant of the After not withdrawal the for baseline of between of in SPPB and early The score XX the two the Changes study scores were points on but in p-value in and very events. no groups difference.
in readiness. Mean liter in difference bicarbonate our per serum and XX.X own liter to No now per results with saw observed sharp our sodium what in trial. was significant XX.X that we and multi-center contrast blinded, the me turn in arm in mind, placebo bicarbonate let milliequivalents was are to veverimer commercial the arm. milliequivalents With These eGFR. placebo-controlled,
to approval the our we’re of our Given of us prelaunch a in year, quarter which discussion to NDA takes third submit veverimer of activities. anticipating plans next year, the this
real-world American Nephrology planning our been awareness disease Week D.C. teams, of for peer database health held We’ve our commercial at Week early November. be and record and from meeting diagnosis intriguing very the the presence present building campaign, major high in acidosis to and discussions continuing medical actual data Kidney At major a plan Society rates. to in XXXE prevalence the metabolic in true gear meeting, medical advancing Washington, and data we of Kidney some its our treatment affairs and versus the
importance recognizing, left They wasting, meeting would the and early of diagnosing disease and effort will seek highlight untreated, progression including consequences Our at loss, treating raise also acidosis. of the bone the of disease mortality serious if awareness the awareness accelerated the to CKD. muscle of metabolic
planned the the this for planned the in for a NDA four the achievement, New veverimer of I Tricida The to than by proud submission investigational I Drug major the has Our new Application of less currently around the working be submission and internal remarks submission want goal, to NDA is a am my veverimer. quarter finalize and a team to giving will aggressive from drug program taking years. application this that quarter to been NDA team clock shout-out an for conclude
I’d turn to the Geoff results discuss Now financial our like call to quarter. for over to the
